transferred on share sale and purchase date from the seller’s connected persons ) and related services i.e. registration with Food and Drug Administration (FDA), trademark permission, product and packaging

. registration with Food and Drug Administration (FDA), trademark permission, product and packaging design, and brand building etc. to customers who are business operator in skin cares and cosmetics. In addition

international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug

granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change

issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures

, e.g., supermarket, food and restaurants (only for takeaway), drug stores.  Online sales continued to grow remarkably by 150.0% YoY.  Gross profit margin from sale of goods improved outstandingly to

% MB % MB % 1. Wellness and Anti-aging 128.58 40.58% 162.70 43.82% 34.12 26.54% 2. Aesthetic Innovation 96.00 30.30% 67.17 18.09% (28.83) (30.03%) 3. Companion Animal Health 80.78 25.50% 132.19 35.60

-634-0225 Fax 02-634-0135 www.interpharma.co.th Type of Revenue 1st Quarter 2020 1st Quarter 2019 Change MB % MB % MB % 1. Wellness & Anti-Aging 47.77 49.18 31.87 37.52 15.90 49.90% 2. Aesthetic

increased in revenues from sales of medicated pet shampoo, pet foods products, livestock animal products, and revenues from sales of wellness & anti-aging products and aesthetic innovations products. 2. Cost

shares of WCI Holding PCL, held by EFORL. As coronavirus situation may impact to the business which is unable to be expected, the Board of Director meeting considers that the investment in wellness